PREDILIFE
ISIN: FR0010169920 | Ticker: ALPRE | LEI: 9695006IK5NBKHQU9116
Country: France
Pioneers of predictive medicine in France, we position ourselves as a player in 6P medicine: Predictive, Preventive, Personalized, Participative, Relevant, Multi-professional.
After 14 years of research and development, Predilife obtained its medical device certification and began marketing predictive assessments: predictive breast cancer assessment, multi-pathology predictive assessments.
At Predilife, we are passionate about serving health, a committed team that works every day to change the rules so that our motto "predict to prevent" is adopted by the greatest number of people.
We accompany companies, healthcare professionals and employees towards the medicine of tomorrow: predictive, personalized and digital. We are working to make predictive medicine accessible to everyone in order to reduce the number of serious diseases.
We believe that predictive medicine will enable effective prevention and thus reduce the risk of serious diseases.
2004
Served areaWorldwide
Headcount19
Headquarters39 Rue Camille Desmoulins, 94800 Villejuif – France
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 22.09.23 | None | Other | Buy | EUR 5,200.00 |
| 22.08.23 | None | Other | Buy | EUR 5,700.00 |
| 28.07.23 | None | Other | Other | EUR 3,990.00 |
| 26.07.23 | None | Other | Buy | EUR 6,840.00 |
| 20.07.23 | None | Other | Other | EUR 7,080.00 |
| 02.05.23 | None | Other | Buy | EUR 17,700.00 |
| 01.03.23 | None | Other | Buy | EUR 24,000.00 |
FR0010169920
LEI9695006IK5NBKHQU9116
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.